Among the five samples with discordant KRAS mutational status in the two body sources (27.8%), KRAS mutations were detected only in the DF (two PDAC patients, one CCA patient, and one control) or plasma (one PDAC patient) samples; notably, the discordance rate was greater in the patients than in the controls (40% vs. 12.5%). This evidence concerns the gene KRAS and cholangiocarcinoma.